Teladoc Appoints New CFO, Charles Schneider
Ticker: TDOC · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1477449
| Field | Detail |
|---|---|
| Company | Teladoc Health, Inc. (TDOC) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001, $800,000, $15,000,000, $9,700,000, $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, cfo, personnel-change
TL;DR
Teladoc just hired a new CFO, Chuck Schneider, starting June 10th. New era for finances?
AI Summary
Teladoc Health, Inc. announced on June 5, 2024, the appointment of Charles R. "Chuck" Schneider as its new Chief Financial Officer, effective June 10, 2024. Schneider previously served as CFO of Accolade, Inc. and will receive an annual base salary of $475,000, along with other compensation and equity awards.
Why It Matters
The appointment of a new CFO can signal strategic shifts or a focus on financial stability and growth for the company.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.
Key Numbers
- $475,000 — CFO Annual Base Salary (This is the starting base salary for the new Chief Financial Officer.)
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- Charles R. "Chuck" Schneider (person) — Newly appointed Chief Financial Officer
- $475,000 (dollar_amount) — Annual base salary for new CFO
- June 10, 2024 (date) — Effective date for new CFO
- Accolade, Inc. (company) — Previous employer of new CFO
FAQ
What is Charles R. Schneider's previous experience?
Charles R. Schneider previously served as the Chief Financial Officer of Accolade, Inc.
When is Charles R. Schneider's appointment effective?
The appointment of Charles R. Schneider as Chief Financial Officer is effective June 10, 2024.
What is the annual base salary for the new CFO?
The annual base salary for Charles R. Schneider is $475,000.
What other compensation will the new CFO receive?
In addition to his base salary, Mr. Schneider will be eligible for other compensation and equity awards as determined by the Compensation Committee.
What was the previous company of the new CFO?
The previous company where Charles R. Schneider served as CFO was Accolade, Inc.
Filing Stats: 2,260 words · 9 min read · ~8 pages · Grade level 12 · Accepted 2024-06-10 16:05:15
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha
- $800,000 — ovides for (i) an annual base salary of $800,000, (ii) eligibility to receive an annual
- $15,000,000 — aggregate target value of approximately $15,000,000, which were issued on June 10, 2024 in
- $9,700,000 — egate grant date fair value of at least $9,700,000 in 2025, which are expected to be issue
- $20,000 — o receive a relocation benefit equal to $20,000 per month for the first 12 months. In
Filing Documents
- tdoc-20240605.htm (8-K) — 49KB
- exhibit101.htm (EX-10.1) — 146KB
- exhibit102.htm (EX-10.2) — 90KB
- exhibit103.htm (EX-10.3) — 23KB
- exhibit104.htm (EX-10.4) — 5KB
- exhibit9913.htm (EX-99.1) — 9KB
- image_0a.jpg (GRAPHIC) — 156KB
- 0001477449-24-000157.txt ( ) — 724KB
- tdoc-20240605.xsd (EX-101.SCH) — 2KB
- tdoc-20240605_lab.xml (EX-101.LAB) — 22KB
- tdoc-20240605_pre.xml (EX-101.PRE) — 13KB
- tdoc-20240605_htm.xml (XML) — 3KB
01. Regulation FD
Item 7.01. Regulation FD. On June 10, 2024, the Company issued a press release regarding the appointment of Mr. Divita as Chief Executive Officer of the Company. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished under this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1 0.1 O ffer Letter , dated June 5 , 2024, by and between Teladoc Health, Inc. and Charles D ivita . 1 0.2 E mployment Agreement, dated June 10 , 2024 , by and between Teladoc Health, Inc. and Charles Divita . 10. 3 Amendment No. 2 to Executive Severance Agreement, dated June 6 , 2024, by and between Teladoc Health, Inc. and Mala Murthy. 1 0.4 First Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan. 99.1 Teladoc Health, Inc. press release, dated June 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 10, 2024 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary